Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically or cytologically confirmed metastatic or recurrent RCC (any histologic subtype)~* Patients must have between 1 to 5 new or recurrent lesions suspicious for metastatic RCC on diagnostic imaging~  * Each extracranial lesion must be =\< 6 cm and amenable to SBRT or surgical excision~ * Patients must have 3 or fewer brain metastases, of size =\< 4 cm~    * Brain metastases must be treated prior to enrollment in the study; the modality of treatment of brain metastases can include surgical resection, whole brain radiotherapy, stereotactic radiosurgery, or any combination of the above~ * Patients who have an intact unresected primary tumor should be considered for radical nephrectomy and primary resection prior to enrollment in the study; if the patient is not eligible for surgical resection, the primary tumor must be amenable to SBRT or request for applications (RFA); generally, this will be defined as a primary tumor \< 10 cm in size or a primary lesion which can be treated to a dose of \>= 8 Gy x 5 without excessive perceived risk of toxicity~* Patients must have had at least a computed tomography (CT) of the chest, abdomen, and pelvis within 4 weeks of registration in the trial; CT or magnetic resonance imaging (MRI) of the brain is only required in the presence of neurologic symptoms~* Patients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 month~* Patients may not have had prior bevacizumab, based on case reports of tracheoesophageal fistula in patients treated with bevacizumab and radiotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status =\<2~* Age 18 years or older~* Life expectancy of \>= 3 months~* Patients must have normal organ and marrow function within 30 days of registration, as defined below:~  * Absolute neutrophil count \>= 500/mcL~ * Hemoglobin \>= 8.0 g/dL~ * Platelets \>= 50,000/mcL~ * Total bilirubin within normal institutional limits~ * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3 X institutional upper limit of normal if liver metastases are present~* Women of childbearing potential must have a negative pregnancy test within 14 days of registration~* Patients must have the ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Patients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollment~* Patients who have had any prior bevacizumab, due to case reports suggesting a possible risk of severe toxicity in combination with radiotherapy~* Patients with radiographic or clinical findings of spinal cord compression or cauda equina syndrome with neurologic deficit thought to be due to malignancy~* Patients may not be receiving any systemic anti-cancer agents or other investigational agents during radiation therapy~* Patients may not have received prior radiation therapy to a site of recurrence which would require overlap of appreciable radiation dose~* Known active invasive malignancy except for renal cell carcinoma and/or non-melanoma skin cancer~* Severe, active co-morbidity, defined as follows:~  * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration;~ * Transmural myocardial infarction within the last 6 months prior to registration;~ * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days prior to registration;~ * Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;~ * Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)4 count \< 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count \>= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol~* Pregnancy or women of childbearing potential who are sexually active and not willing/able to use medically acceptable forms of contraception during protocol treatment or for at least 6 months following treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stereotactic body radiation therapy (Type: EXPERIMENTAL): Patients undergo stereotactic body radiation therapy on day 1 over 3 times a week for 28 days in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues